egfr inhibitor
Recently Published Documents


TOTAL DOCUMENTS

564
(FIVE YEARS 167)

H-INDEX

42
(FIVE YEARS 8)

2021 ◽  
Author(s):  
Yingqiang Liu ◽  
Mengzhen Lai ◽  
Shan Li ◽  
Yanan Wang ◽  
Fang Feng ◽  
...  
Keyword(s):  

2021 ◽  
Vol 41 ◽  
pp. 100419
Author(s):  
Shotaro Uehara ◽  
Nao Yoneda ◽  
Yuichiro Higuchi ◽  
Hiroshi Yamazaki ◽  
Hiroshi Suemizu

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Toshinori Ando ◽  
Nadia Arang ◽  
Zhiyong Wang ◽  
Daniela Elena Costea ◽  
Xiaodong Feng ◽  
...  

AbstractThe Hippo pathway is frequently dysregulated in cancer, leading to the unrestrained activity of its downstream targets, YAP/TAZ, and aberrant tumor growth. However, the precise mechanisms leading to YAP/TAZ activation in most cancers is still poorly understood. Analysis of large tissue collections revealed YAP activation in most head and neck squamous cell carcinoma (HNSCC), but only 29.8% of HNSCC cases present genetic alterations in the FAT1 tumor suppressor gene that may underlie persistent YAP signaling. EGFR is overexpressed in HNSCC and many other cancers, but whether EGFR controls YAP activation is still poorly understood. Here, we discover that EGFR activates YAP/TAZ in HNSCC cells, but independently of its typical signaling targets, including PI3K. Mechanistically, we find that EGFR promotes the phosphorylation of MOB1, a core Hippo pathway component, and the inactivation of LATS1/2 independently of MST1/2. Transcriptomic analysis reveals that erlotinib, a clinical EGFR inhibitor, inactivates YAP/TAZ. Remarkably, loss of LATS1/2, resulting in aberrant YAP/TAZ activity, confers erlotinib resistance on HNSCC and lung cancer cells. Our findings suggest that EGFR-YAP/TAZ signaling plays a growth-promoting role in cancers harboring EGFR alterations, and that inhibition of YAP/TAZ in combination with EGFR might be beneficial to prevent treatment resistance and cancer recurrence.


Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5394
Author(s):  
Ramya Thota ◽  
Mingli Yang ◽  
Lance Pflieger ◽  
Michael J. Schell ◽  
Malini Rajan ◽  
...  

Recently, it was suggested that consensus molecular subtyping (CMS) may aide in predicting response to EGFR inhibitor (cetuximab) therapies. We recently identified that APC and TP53 as two tumor suppressor genes, when mutated, may enhance cetuximab sensitivity and may represent easily measured biomarkers in tumors or blood. Our study aimed to use APC and TP53 mutations (AP) to refine the CMS classification to better predict responses to cetuximab. In total, 433 CRC tumors were classified into CMS1-4 subtypes. The cetuximab sensitivity (CTX-S) signature scores of AP vs. non-AP tumors were determined across each of the CMS classes. Tumors harboring combined AP mutations were predominantly enriched in the CMS2 class, and to a lesser degree, in the CMS4 class. On the other hand, AP mutated CRCs had significantly higher CTX-S scores compared to non-AP CRCs across all CMS classes. Similar results were also obtained in independent TCGA tumor collections (n = 531) and in PDMR PDX/PDO/PDC models (n = 477). In addition, the in vitro cetuximab growth inhibition was preferentially associated with the CMS2 cell lines harboring A/P genotypes. In conclusion, the AP mutation signature represents a convenient biomarker that refines the CMS classification to identify CRC subpopulations predicted to be sensitive to EGFR targeted therapies.


2021 ◽  
Vol 5 (1) ◽  
Author(s):  
T. L. Peters ◽  
T. Patil ◽  
A. T. Le ◽  
K. D. Davies ◽  
P. M. Brzeskiewicz ◽  
...  

AbstractEGFR mutant non-small cell lung cancer patients' disease demonstrates remarkable responses to EGFR-targeted therapy, but inevitably they succumb to acquired resistance, which can be complex and difficult to treat. Analyzing acquired resistance through broad molecular testing is crucial to understanding the resistance mechanisms and developing new treatment options. We performed diverse clinical testing on a patient with successive stages of acquired resistance, first to an EGFR inhibitor with MET gene amplification and then subsequently to a combination EGFR and MET targeted therapies. A patient-derived cell line obtained at the time of disease progression was used to identify NRAS gene amplification as an additional driver of drug resistance to combination EGFR/MET therapies. Analysis of downstream signaling revealed extracellular signal-related kinase activation that could only be eliminated by trametinib treatment, while Akt activation could be modulated by various combinations of MET, EGFR, and PI3K inhibitors. The combination of an EGFR inhibitor with a MEK inhibitor was identified as a possible treatment option to overcome drug resistance related to NRAS gene amplification.


Author(s):  
Pinelopi Voulgari ◽  
Dimitrios Alivertis ◽  
Konstantinos Skobridis

2021 ◽  
pp. candisc.0715.2021
Author(s):  
Pasi A. Janne ◽  
Christina Baik ◽  
Wu-Chou Su ◽  
Melissa L Johnson ◽  
Hidetoshi Hayashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document